Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Valeant Pharma (VRX) Reports Q1 EPS of $2.36; Announces CFO Transition
April 29, 2015 6:00 AM EDT
LAVAL, Quebec, April 29, 2015 /PRNewswire/ --
2015 First Quarter Results
Total Revenue $2.2 billion; an increase of 16% over the prior year despite negative foreign exchange impact of $140 million
Excluding negative impact of foreign exchange and last year's divestiture of the aesthetics injectable business, revenue increased 27% over the prior year
Same Store Sales Organic Growth was 15%, driven by:
Growth from launch brands, including BioTrue Multipurpose Solution, BioTrue ONEday Contact Lens, Jublia, Luzu, and Ultra Contact Lens
Double digit...
More
April 29, 2015 6:00 AM EDT
LAVAL, Quebec, April 29, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Howard B. Schiller has advised the Company of his decision to step down as Chief Financial Officer once a successor is appointed. In order to facilitate a smooth transition, Mr. Schiller will remain in his current position as the search for his replacement proceeds. Â With the support of Valeant's Board of Directors, Mr. Schiller will remain on the Valeant Board and, with the Board's continued recommendation,... More
